NasdaqHealth CareHealth Care FacilitiesS&P SmallCap 600
$34.50
-4.51 (-11.56%)
Close of Nov 06, 2026 · end-of-day data
ASTH 8-K filings in 2026
Every material Form 8-K Astrana Health filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Astrana Health reported third-quarter 2026 results on November 5, 2026, with revenue of $1,023.6 million, up 7%, and net income attributable to Astrana of $13.0 million, up from $0.4 million a year earlier. The company also narrowed its full-year 2026 guidance for revenue, adjusted EBITDA and free cash flow and gave fourth-quarter guidance; the filing does not state prior guidance, so the direction of the change is not shown. For shareholders, headline profit and revenue both improved, while adjusted EPS rose 4% to $0.71.
Q3 2026 total revenue $1,023.6 million, up 7%; adjusted EBITDA $77.2 million, up 13%
Net income attributable to Astrana $13.0 million vs $0.4 million; diluted EPS $0.26 vs $0.01
Adjusted EPS - diluted $0.71, up 4% from $0.68
Full-year 2026 guidance: total revenue $3.9 billion to $4.0 billion; adjusted EBITDA $261 million to $274 million; free cash flow $107.5 million to $130 million
Astrana Health said social engineering attacks, in which threat actors impersonated company personnel and spoofed its main phone number, led to unauthorized activity in its environment. The company has determined the incident is material and believes certain private or confidential information was accessed or acquired, but the full scope remains under investigation. The company currently does not expect a material effect on its financial condition and results of operations, though it cannot yet estimate the full impact.
Company determined the incident is material as of September 22, 2026, citing the potential confidential and sensitive nature of the data involved.
Threat actors impersonated Company personnel and spoofed the main corporate telephone number to contact employees seeking unauthorized system access.
Company engaged a third-party forensics firm, notified law enforcement, and is notifying state and federal regulators and payer partners.
Company maintains cybersecurity insurance but says coverage may not be sufficient to cover all losses.
Astrana Health reported second-quarter 2026 revenue of $972.5 million, up 49% from a year earlier, and net income attributable to Astrana of $19.7 million, up 109%. The company raised its full-year 2026 adjusted EBITDA guidance to $255 million to $280 million and reaffirmed its revenue and free cash flow guidance, which points to stronger profitability for shareholders.
Q2 2026 diluted EPS was $0.40, up 111% from $0.19; adjusted EBITDA was $68.9 million, up 43%
Full-year 2026 adjusted EBITDA guidance is $255 million to $280 million; full-year revenue guidance of $3.8 billion to $4.1 billion was reaffirmed
Q3 2026 revenue guidance is $1.00 billion to $1.03 billion; Q3 adjusted EBITDA guidance is $72.5 million to $77.5 million
Care Partners income from operations fell 14% in Q2, and the Care Delivery segment posted an operating loss of $3.0 million
Astrana Health said its Chief Accounting Officer and principal accounting officer, Glenn Sobotka, will retire effective August 7, 2026, with the company saying the decision does not reflect any disagreement on operations, policies, or practices. John Vong, previously the company's Group Vice President, Accounting, will succeed him as principal accounting officer on that date. The change is administrative in nature and does not alter reported financial results.
Glenn Sobotka retires as Chief Accounting Officer effective August 7, 2026; the agreement was reached June 25, 2026
John Vong becomes Senior Vice President, Accounting effective July 1, 2026, and principal accounting officer on August 7, 2026
Vong's annual base salary rises to $320,000 effective July 1, 2026; his 2026 target bonus percentage is unchanged
At its June 10, 2026 annual meeting, Astrana Health stockholders approved an amended and restated 2024 Equity Incentive Plan that adds 1,000,000 shares to the reserve and extends the plan to March 24, 2036. All nine director nominees were elected, and the auditor ratification, advisory pay vote, and plan approval all passed, which matters to shareholders because it sets the company's equity compensation framework for the next decade.
Plan amendment adds 1,000,000 shares to the reserve and extends the term to March 24, 2036.
Nine directors were elected, each to serve until the 2027 annual meeting.
Ernst & Young LLP ratified as auditor for fiscal 2026 with 43,722,509 votes for.
Shareholders holding about 78.6% of eligible votes were present, and the advisory executive pay proposal passed with 34,119,199 votes for.
Astrana Health disclosed that Chief Medical Officer Dinesh Kumar, M.D., notified the company on May 7, 2026, of his intention to resign effective June 1, 2026. The company said the resignation is not the result of any disagreement with the company, and the filing contains no replacement details or financial results.
Dinesh Kumar, M.D., Chief Medical Officer, notified the company of his resignation on May 7, 2026.
Resignation is effective June 1, 2026.
The company states the departure is not due to any disagreement with the company.
Astrana Health reported first-quarter 2026 revenue of $965.1 million, up 56% from a year earlier, and net income attributable to the company of $14.4 million, up 116%. The company reiterated its full-year 2026 revenue and Adjusted EBITDA guidance and gave a second-quarter outlook, so shareholders see both higher reported profit and a steady forecast.
Total revenue of $965.1 million, up 56% from $620.4 million; diluted EPS of $0.29 versus $0.14
Net income attributable to Astrana of $14.4 million, up 116% from $6.7 million; Adjusted EBITDA of $66.3 million, up 82%
Q2 2026 guidance: total revenue of $965 million to $1,000 million and Adjusted EBITDA of $65 million to $70 million
Full-year 2026 guidance reiterated: total revenue of $3.8 billion to $4.1 billion and Adjusted EBITDA of $250 million to $280 million
Astrana Health reported full-year 2025 revenue of $3.18 billion, up 56%, and fourth-quarter revenue of $950.5 million, up 43%. Full-year GAAP net income attributable to the company fell to $22.5 million from $43.1 million, and the company said it expects to report a material weakness in internal control over financial reporting, which will delay its annual report on Form 10-K.
Full-year 2025 revenue of $3,181.8 million, up 56%; adjusted EBITDA of $205.4 million, up 21%
Full-year 2025 diluted EPS of $0.46 versus $0.90 in 2024; adjusted diluted EPS of $2.20 versus $1.94
Company will file Form 12b-25 to extend the 10-K deadline, expects a material weakness tied to acquisition and purchase accounting, and expects to file within the 15-day extension period
Board raised the share repurchase authorization from $50 million to $100 million; $35.9 million remained available as of December 31, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Astrana Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →